Barclays Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $35.00

Hims & Hers Health (NYSE:HIMS) had its price objective reduced by Barclays from $39.00 to $35.00 in a research note released on Friday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

HIMS has been the subject of several other reports. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Bank of America boosted their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $32.17.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $33.67 on Friday. The company’s 50 day simple moving average is $32.37 and its 200-day simple moving average is $26.14. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of -53.44 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same period in the previous year, the business posted $0.17 EPS. The business’s revenue for the quarter was up 38.2% on a year-over-year basis. As a group, equities research analysts expect that Hims & Hers Health will post -0.14 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 4,938 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62. Following the sale, the chief financial officer owned 264,117 shares of the company’s stock, valued at approximately $7,920,868.83. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This represents a 11.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 186,769 shares of company stock worth $6,035,648 over the last 90 days. 11.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Versant Capital Management Inc raised its position in Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after buying an additional 319 shares during the period. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Bogart Wealth LLC grew its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares in the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health during the first quarter worth about $30,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Analysts and investors see continued expansion opportunities in branded GLP-1 weight-loss products, testosterone, peptides, international markets and AI-driven patient support. These initiatives could strengthen revenue growth and improve operating efficiency over time. What is driving HIMS stock’s rally
• Positive Sentiment: Barclays maintained an “overweight” rating, indicating a favorable long-term view even after reducing its price target from $39 to $35. The revised target remains above the referenced trading level. Barclays price-target update
• Neutral Sentiment: Recent insider sales by CFO Oluyemi Okupe and other executives were made under pre-arranged Rule 10b5-1 plans. While the transactions may create a modest overhang, the insiders continued to hold sizable positions, reducing the signal that management confidence has materially weakened. HIMS insider sales
• Neutral Sentiment: Analyst views remain divided. Needham raised its price target to $42 and kept a Buy rating, while the broader consensus remains Hold, reflecting strong revenue growth but uncertainty around margins and the GLP-1 strategy.
• Negative Sentiment: Three law firms announced investigations into potential securities-law violations. These announcements are investor outreach notices—not findings of wrongdoing—but they add legal, compliance and reputational risk amid scrutiny of privacy practices, billing and subscription cancellations. Kaplan Fox investigation
• Negative Sentiment: The latest quarterly results showed revenue of $753.2 million, up 38.2% year over year and above expectations, but the company reported a $0.37-per-share loss versus the expected $0.05 loss. Persistent losses and weak profitability could limit further upside unless margins improve.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.